Keyword: Juno Therapeutics
Allogene Therapeutics has nearly tripled its IPO goal, pricing the deal at the high end of the range and raising $288 million.
Alder hires Juno exec as CEO, Allergan brings in Abbott vet after investors demand change, and ResTORbio poaches Novartis researcher as clinical VP.
Nadim Ahmed said Celgene’s arm’s-length relationship with the biotech it bought for $7.2 billion three years ago led to a substandard filing.
Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.
Gregory Verdine’s FogPharma raised $66 million in series B financing, with hopes to bring its first product to the clinic by the end of next year.
A CAR-T biotech formed by Juno and WuXi got off a $90 million series A with Chinese backing, as it eyes clinical trials of its new cancer therapy.
We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands of the biotech industry. This year, we’re at it again with a bit of a twist: We included companies bruised in 2016 but revived in 2017.
Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position in the cell therapy space.
Celgene agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal instantly making it a big cheese in therapeutics.